Atrial Fibrillation Market Report 2026

Atrial Fibrillation Market Overview

• Atrial Fibrillation market size has reached to $15.1 billion in 2025 • Expected to grow to $27.88 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Increase In Cardiovascular Diseases Drives The Market • Market Trend: Innovative Products Revolutionize Atrial Fibrillation Patient Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atrial Fibrillation Market?

Atrial fibrillation refers to a disorder of the heart caused by an abnormality in the normal sequence of electrical impulses that changes the rate or rhythm at which the heart beats and begins in the heart's upper chambers (atria). Electrical impulses can be too fast, too slow, or erratically occurring, resulting in irregular heartbeats. The main types of atrial fibrillation involve surgical and non-surgical. Surgical atrial fibrillation treatment refers to a procedure in which a patient receives an electrical shock on the outside of the chest to regulate the heartbeat using either paddles or patches. The technologies, including radiofrequency, laser, cryotherapy, and others, are used for treatments including pharmacological, non-pharmacological, maze surgery, and electric cardioversion. They are used by various end-users, such as hospitals, electrophysiology labs, and ambulatory surgical centers.

What Is The Atrial Fibrillation Market Growth Forecast?

The atrial fibrillation market size is expected to see rapid growth in the next few years. It will grow to $27.88 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to increasing demand for personalized arrhythmia treatment, rising adoption of wearable cardiac monitoring devices, expansion of hybrid treatment approaches, growing investments in electrophysiology infrastructure, increasing focus on long-term rhythm management outcomes. Major trends in the forecast period include increasing adoption of catheter ablation procedures, rising use of advanced cardiac mapping systems, growing preference for minimally invasive treatments, expansion of pharmacological rhythm control therapies, enhanced focus on early diagnosis and monitoring.

Global Atrial Fibrillation Market Segmentation

1) By Type: Surgical, Non-Surgical 2) By Technology: Radiofrequency, Laser, Cryotherapy, Other Technologies 3) By Treatment Type: Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, Electric Cardioversion 4) By End User: Hospitals, Electrophysiology Labs, Ambulatory Surgical Centers Subsegments: 1) By Surgical: Catheter Ablation, Maze Procedure, Hybrid Ablation Procedures 2) By Non-Surgical: Antiarrhythmic Drugs, Anticoagulants, Cardioversion Procedures

What Is The Driver Of The Atrial Fibrillation Market?

The increase in the cardiovascular diseases is expected to drive the atrial fibrillation market forward. Cardiovascular diseases refer to a class of disorders affecting the heart and blood vessels, encompassing conditions such as coronary artery disease, heart failure, and arrhythmias, posing a significant risk to overall cardiovascular health. The surge in cardiovascular conditions underscores the growing demand for advanced diagnostic and treatment solutions, driving the atrial fibrillation market forward as healthcare systems and industries respond to the escalating challenges posed by the increasing incidence of these diseases. For instance, in October 2024, according to CDC (Centers for Disease Control and Prevention), U.S-based government agency, reported that, in 2023, 919,032 people died from cardiovascular disease. That's the equivalent of 1 in every 3 deaths. Further, every year about 805,000 people in the United States have a heart attack. Therefore, the high burden of cardiovascular diseases worldwide will drive the atrial fibrillation industry.

Key Players In The Global Atrial Fibrillation Market

Major companies operating in the atrial fibrillation market are AtriCure Inc, Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Johnson & Johnson, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Sanofi SA, Bayer AG, Pfizer Inc, Daiichi Sankyo Company Limited, AstraZeneca PLC, Biotronik SE & Co KG, Kardium Inc, Acutus Medical Inc, Apama Medical Inc, CardioFocus Inc, AliveCor Inc, iRhythm Technologies Inc, BioSig Technologies Inc

Global Atrial Fibrillation Market Trends and Insights

Major companies in the atrial fibrillation market are launching innovative products and solutions, such as patient-centric clinical decision support tools, to strengthen their position in the market. Clinical decision support tools (CDST) are software or electronic systems designed to assist healthcare professionals in making informed and timely decisions about patient care. These tools are developed to integrate relevant clinical information from various sources. For instance, in August 2023, GE HealthCare, a US-based multinational medical technology company, launched the CardioVisio, a patient-centered clinical decision support tool to help doctors drive evidence-based clinical decision support guided by current atrial fibrillation guidelines and visualize longitudinal data from various data sources relevant for illness progression. CardioVisio for atrial fibrillation can assist cardiologists with streamlining clinician image interpretation and providing a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.

What Are Latest Mergers And Acquisitions In The Atrial Fibrillation Market?

In February 2025, Novartis, a Switzerland-based pharmaceutical company, acquired Anthos Therapeutics, Inc., for $925 million upfront, with potential milestone payments up to $2.15 billion. Through this acquisition, Novartis aims to enhance its atrial fibrillation treatment portfolio by integrating Anthos’s FXI-inhibiting therapy, abelacimab, for stroke prevention in AF patients. Anthos Therapeutics, Inc. is a U.S.-based biopharmaceutical company that develops abelacimab, a monoclonal antibody targeting Factor XI to prevent stroke and systemic embolism in patients with atrial fibrillation.

Regional Outlook

North America was the largest region in the atrial fibrillation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the atrial fibrillation market report forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Atrial Fibrillation Market?

The atrial fibrillation market includes revenues earned by entities from treatment for sinus bradycardia, premature atrial contractions (PACS), wandering atrial pacemakers, atrial tachycardia, multifocal atrial tachycardia, atrial flutter, and atrial fibrillation (AFib). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atrial Fibrillation Market Report 2026?

The atrial fibrillation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.